Our coronavirus capsule reduces the chance of hospitalization and demise by 89 %
‘FIZER’ COMPANY ANNOUNCED: Our corona virus pill reduces the risk of hospitalization and death by 89 percent
The company “Pfizer” announced on Friday that its experimental antiviral pill for Kovid-19 reduced the hospitalization and death rate by almost 90% in adults who have a chance of getting seriously ill.
The trial has been shortened, and “Pfizer” intends to submit a request for approval of the use of the pill to the Federal Agency for Food and Medicines.
This result exceeds the percentage of efficiency that the company “Merk” determined for its pill “molnupiravir”, which last month showed that it can halve the chances of dying or hospitalization of people with kovid who are at risk of serious illness.
The pizer pill is called “paxlovid”, and it is taken in three pieces twice a day.
The trial involved 1,219 patients who had a mild or moderate form of covid and at least one risk factor for developing a more severe form, including obesity or older age.
It was determined that 0.8 percent of the people from the group who took the pills ended up in the hospital within three days after they developed symptoms, and none of them died within 28 days after the treatment.
In patients receiving placebo, that percentage was seven percent. Eight people died in the placebo group.
The rates were similar five days after the onset of symptoms – one percent of those treated with the pills were hospitalized, and in the placebo group the percentage was 6.7 percent and ten people died in them.
The antiviral pill should be taken as early as possible, before the infection develops, because then the best effect is achieved.
Merck tested his pill for five days after the onset of symptoms.
The announcement came a day after the UK became the first country to give the green light to Merck’s coronavirus pill.
Currently, all covid-19 treatments used in the United States require intravenous therapy or injection.